Clinical Trials Browser

Pituitary Neoplasms × Cabergoline × Clear all

NCT07034859 2025-06-24

Cabergoline in the Management of Nonfunctioning Pituitary Adenoma

Phase 4 Enrolling by invitation

Pituitary Neoplasms

NCT02288962 2025-06-08

Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas

Phase 3 Active not recruiting

Adenoma, Pituitary Neoplasms

NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

Phase 4 Completed

337 enrolled 8 charts

DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

NCT01915303 2020-09-18

Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease

Phase 2 Terminated

68 enrolled 25 charts

Adrenocortical Hyperfunction, Pituitary Neoplasms, Pituitary ACTH Hypersecretion

NCT03457389 2020-03-18

Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma

Phase NA Unknown

Pituitary Neoplasms, Recurrence, Prolactinoma

NCT03271918 2017-09-07

Cabergoline in Nonfunctioning Pituitary Adenomas

Phase 3 Completed

Pituitary Neoplasms

NCT00376064 2017-03-06

Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

Phase 4 Completed

Acromegaly, Brain Neoplasms, Pituitary Neoplasms